证券代码：688687 证券简称：凯因科技 公告编号：2025-001 北京凯因科技股份有限公司 2024 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2024年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以北京凯因科技股份有限公司（以下简称"公司"）2024年年度报 告为准，提请投资者注意投资风险。 一、2024 年度主要财务数据和指标 单位：人民币万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | | --- | --- | --- | --- | --- | | 营业总收入 | 123,106.46 | 141,200.62 | | -12.81 | | 营业利润 | 20,267.02 | 17,082.83 | | 18.64 | | 利润总额 | 18,647.05 | 14,624.47 | | 27.51 | | 归属于母公司所有者的净利润 | 14,383.47 | 11,652.50 | | 23.44 | | 归属于母公司所有者 ...

上 海 证 券 交 易 所 上证科创公监函〔2024〕0059 号 关于对北京凯因科技股份有限公司及有关责任 人予以监管警示的决定 定期报告是投资者关注的重大事项，可能对公司股价及投资者 决策产生影响，公司理应根据会计准则对当期财务数据进行客观、 谨慎地核算并披露。公司多期定期报告财务信息披露不准确等行为， 违反了《上海证券交易所科创板股票上市规则》（以下简称《科创板 股票上市规则》）第 5.1.2 条、第 5.1.4 条等有关规定。 1 责任人方面，公司时任董事长兼总经理周德胜作为公司主要负 责人、信息披露第一责任人，时任财务负责人郭伟作为公司财务事 项的具体负责人，根据《行政监管措施决定书》的认定，对公司相 关违规行为负有主要责任，违反了《科创板股票上市规则》第 4.2.1 条、第 4.2.4 条、第 4.2.5 条、第 5.1.2 条等规定及其在《董事（监 事、高级管理人员）声明及承诺书》中做出的承诺。 鉴于上述违规事实和情节，根据《科创板股票上市规则》第 14.2.1 条、第 14.2.2 条和《上海证券交易所纪律处分和监管措施实 施办法》等有关规定，我部作出如下监管措施决定： 对北京凯因科技股份有限 ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2023, representing a 20% increase compared to the same period last year[2]. - The company has set a revenue guidance of 1.2 billion RMB for the full year 2023, indicating a projected growth of 25%[2]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the first half of 2023, representing a 25% year-over-year growth[19]. - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 30% year-over-year[19]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2023, representing a 20% year-over-year growth[161]. - The company reported a revenue increase of 15% year-over-year, reaching $500 million in the latest quarter[170]. - The company reported a significant increase in revenue, achieving a total of 550 million yuan in the first half of 2023, marking a year-on-year growth of 25%[176]. User Growth - User data showed a growth in active users to 1.2 million, up 15% year-over-year[2]. - User data indicates a growth in active users, reaching 500,000, which is a 40% increase compared to the previous year[19]. - User data showed a growth in active users, reaching 10 million, which is a 15% increase compared to the previous year[164]. - User data showed a growth of 20% in active users, totaling 2 million users by the end of the reporting period[171]. Product Development and R&D - New product launches contributed to 30% of total revenue, with significant demand in the biotechnology sector[2]. - The company is investing 100 million RMB in R&D for new technologies, focusing on innovative drug development[2]. - New product launches include the innovative antiviral drug, which is expected to generate an additional 200 million CNY in revenue by the end of the year[19]. - Research and development investments have increased by 20%, focusing on new drug formulations and delivery methods[19]. - The company’s R&D investment as a percentage of operating revenue was 10.49%, a decrease of 4.11 percentage points from 14.60% in the previous year[28]. - The company’s R&D investment totaled CNY 56.14 million, accounting for 10.49% of operating revenue, with 7 domestic invention patents applied and 3 granted during the reporting period[81]. - The company is investing $50 million in R&D for new technologies aimed at enhancing user experience[171]. Market Expansion - Market expansion efforts have led to a 10% increase in market share in the Asia-Pacific region[2]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2024[19]. - The company is currently developing a combination of functional cure drugs for hepatitis B and expanding its pipeline in the field of immune diseases[38]. - The company plans to enhance customer engagement through a new loyalty program, expected to increase customer retention by 20%[165]. - Market expansion plans include entering three new international markets by Q4 2023, aiming for a 10% market share in each[165]. Strategic Partnerships and Acquisitions - A strategic partnership was established with a leading pharmaceutical company to co-develop new therapies[2]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence[2]. - A new strategic partnership has been established with a leading biotechnology firm to co-develop next-generation therapies[19]. - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the tech sector[164]. Financial Position and Risks - The net profit attributable to shareholders decreased by 1.16% to ¥36,805,406.75 from ¥37,236,855.77 year-on-year[28]. - The net cash flow from operating activities fell significantly by 168.18%, resulting in a negative cash flow of ¥46,464,411.63, compared to a positive cash flow of ¥68,147,724.38 last year[28]. - The company has identified key risks, including regulatory changes and market competition, which are detailed in the risk factors section[2]. - The company faces risks related to new drug development, including potential clinical trial failures and regulatory changes, which could impact future revenue[89]. Environmental and Compliance - The company has established pollution prevention facilities with normal operation, including a wastewater treatment facility with a capacity of 300 tons per day[137]. - The company has maintained compliance with air and water pollution discharge standards throughout the reporting period[136]. - The company has developed an environmental self-monitoring plan and conducts monitoring through qualified third-party testing agencies, with real-time data being supervised by environmental authorities[141]. - The company has committed to avoiding and minimizing related party transactions, ensuring fair pricing in such transactions[148]. Shareholder Commitments - The controlling shareholder has pledged to hold shares for a minimum of 36 months post-IPO and will not transfer or manage shares during the lock-up period[150]. - Shareholder commitments include a promise not to sell shares for 36 months post-IPO, ensuring stability during the initial growth phase[162]. - The company commits to comply with regulations regarding shareholder reductions and will announce any reduction plans three trading days in advance[156].

根据《上市公司信息披露管理办法》（证监会令第182号）第五十一条、第五 十二条的规定，我局决定对你们采取责令改正的监管措施，并记入证券期货市场 诚信档案。你公司应该按照相关法律法规要求，提高财务核算规范化水平和信息 披露质量，依法履行信息披露义务，并于收到本决定书之日起15个工作日内向我 局报送书面整改报告。 如果对本监管措施不服，可以在收到本决定书之日起 60 日内向中国证券监 证券代码：688687 证券简称：凯因科技 公告编号：2024-055 北京凯因科技股份有限公司 关于收到《中国证券监督管理委员会北京监管局行政 监管措施决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京凯因科技股份有限公司于 2024 年 12 月 19 日收到中国证券监督管理委 员会北京监管局出具的《行政监管措施决定书》〔2024〕303 号，现将相关情况 公告如下： 一、《行政监管措施决定书》的主要内容 北京凯因科技股份有限公司、周德胜、郭伟： 经查，北京凯因科技股份有限公司（以下简称公司）存在以下问题：收入核 算管理不到 ...

2023 年第一季度报告 单位：元 币种：人民币 证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期 增减变动幅度 (%) | | 营业收入 | 159,332,225.42 | -7 ...

Financial Performance - The company's operating revenue for Q3 2023 reached ¥451,759,202.77, representing a year-on-year increase of 31.38%[6] - Net profit attributable to shareholders for Q3 2023 was ¥47,259,179.24, reflecting a significant increase of 51.68% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥48,384,333.38, up by 41.17% year-on-year[6] - Basic earnings per share for Q3 2023 were ¥0.28, up by 55.56% compared to the same period last year[10] - The net profit attributable to shareholders for the year-to-date period increased by 22.91% compared to the same period last year[12] - Net profit for the third quarter of 2023 was ¥94,938,760.33, up from ¥65,367,688.01 in the same quarter of 2022, reflecting a growth of approximately 45.4%[36] - The net profit attributable to shareholders of the parent company for the third quarter was ¥84,064,585.99, compared to ¥68,394,595.45 in the same quarter of 2022, reflecting an increase of approximately 22.9%[36] - The total comprehensive income attributable to the parent company reached ¥86,028,250.37, compared to ¥71,970,830.44 in the previous year, reflecting an increase of approximately 19.5%[39] - Basic and diluted earnings per share both increased to ¥0.50 from ¥0.40, marking a 25% growth year-over-year[39] Assets and Liabilities - The total assets as of the end of Q3 2023 amounted to ¥2,301,663,558.17, an increase of 4.16% from the end of the previous year[10] - The total assets as of the end of the reporting period were ¥2,301,663,558.17, compared to ¥2,209,724,972.77 at the end of the previous year, showing an increase of about 4.1%[30] - Total liabilities increased to ¥559,181,329.47 from ¥527,934,808.32, marking a rise of approximately 5.9%[30] - The equity attributable to shareholders of the parent company reached ¥1,721,057,722.32, up from ¥1,675,556,748.68, indicating an increase of about 2.7%[30] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥34,283,548.58, down by 65.38% compared to the previous year[10] - Cash inflow from operating activities totaled ¥976,228,103.10, up from ¥901,980,839.21, indicating a rise of about 8.2%[42] - The net cash flow from operating activities was ¥34,283,548.58, a decrease from ¥99,030,532.23, showing a decline of approximately 65.4%[42] - Cash inflow from investment activities amounted to ¥1,380,358,586.75, compared to ¥1,081,464,632.91, representing an increase of around 27.6%[42] - The net cash flow from investment activities was ¥126,864,704.63, a significant recovery from a negative cash flow of -¥615,586,129.26 in the previous year[42] - The company reported a net increase in cash and cash equivalents of ¥146,332,312.30, contrasting with a decrease of -¥572,651,999.32 in the prior year[42] - Total cash and cash equivalents at the end of the period stood at ¥866,918,251.56, up from ¥580,619,199.10, reflecting an increase of approximately 49.3%[42] Research and Development - The company's R&D investment totaled ¥30,415,977.66 in Q3 2023, accounting for 6.73% of operating revenue, a decrease of 2.34 percentage points year-on-year[10] - Research and development expenses for the third quarter of 2023 amounted to ¥68,195,871.59, slightly down from ¥69,860,306.50 in the previous year[33] Shareholder Information - The company reported a total of 7,787 common shareholders at the end of the reporting period[14] Strategic Focus and Future Outlook - The company has not disclosed any significant new product developments or technological advancements during this reporting period[20] - There are no indications of market expansion or mergers and acquisitions in the current report[20] - The company has not provided specific future guidance or performance outlook for the upcoming quarters[20] - The report does not mention any significant changes in shareholder structure or related party transactions[20] Operating Costs - Total operating revenue for the first three quarters of 2023 reached ¥986,914,134.12, an increase from ¥836,731,606.49 in the same period of 2022, representing a growth of approximately 17.9%[30] - Total operating costs for the first three quarters of 2023 were ¥873,480,654.54, compared to ¥779,995,200.30 in 2022, indicating an increase of about 12.0%[30] Other Financial Metrics - The weighted average return on equity for Q3 2023 was 2.72%, an increase of 0.88 percentage points year-on-year[10] - The company's long-term equity investments were reported at ¥4,314,100.90, a slight decrease from ¥4,371,655.95 at the end of 2022, showing a decline of approximately 1.3%[25] - The total current assets decreased slightly to ¥1,776,318,126.77 from ¥1,794,875,195.52, a decline of about 1.0%[25] - The company's accounts receivable increased to ¥395,853,210.34 from ¥333,297,094.96, reflecting a growth of about 18.7% year-over-year[25] - Inventory levels rose to ¥165,306,646.59, compared to ¥148,810,966.21 at the end of 2022, indicating an increase of approximately 11.0%[25] - The company's deferred income tax liabilities were reported at ¥6,658,707.03, an increase from ¥5,112,008.42 in the previous year[30] - The total assets held for sale were not reported, indicating a potential area for future strategic focus[25] - The company did not report any net profit from the merged entity prior to the merger, consistent with the previous year[39] - The company is not applying new accounting standards or interpretations that would affect the financial statements for the current year[44]

证券代码：688687 证券简称：凯因科技 公告编号：2024-059 北京凯因科技股份有限公司 关于北京证监局行政监管措施决定书的整改报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京凯因科技股份有限公司（以下简称"公司"）于 2024 年 12 月 19 日收 到中国证券监督管理委员会北京监管局（以下简称"北京证监局"）出具的《行 政监管措施决定书》（〔2024〕303 号）（以下简称《决定书》）。 收到上述《决定书》后，公司高度重视，召集相关部门和人员对《决定书》 所述事项进行分析讨论，积极落实整改。针对《决定书》中所涉及问题，严格按 照相关法律、法规和规范性文件以及《公司章程》的要求，结合公司现场检查情 况认真落实自查和梳理，深入分析问题原因，提出整改措施，并形成整改报告如 下： 一、存在的问题及整改措施 （一）问题一：收入核算管理不到位，2023年一季报、半年报、三季报存在 收入跨期，相关信息披露不准确。 整改措施：根据《企业会计准则第 28 号——会计政策、会计估计变更和差 错更正》《公开发行证券的公司 ...

证券代码：688687 证券简称：凯因科技 公告编号：2024-057 北京凯因科技股份有限公司 第六届监事会第四次会议决议公告 二、监事会会议审议情况 会议以投票表决方式审议并通过了如下决议： （一）审议通过了《关于公司前期会计差错更正及财务报告、前期公告补 充披露的议案》 经审核，监事会认为公司本次前期会计差错更正及追溯调整符合《企业会计 准则第 28 号——会计政策、会计估计变更和差错更正》《公开发行证券的公司信 息披露编报规则第 19 号——财务信息的更正及相关披露》等相关规定，更正后 的信息能够更加客观、公允地反映公司的财务状况和经营成果。董事会关于本次 会计差错更正及追溯调整事项的审议和表决程序符合法律、法规以及《公司章程》 的相关规定，不存在损害公司及全体股东利益的情形，同意公司本次会计差错更 正及追溯调整事项。 表决结果：3票同意，0票反对，0票弃权。 具体内容详见公司登载于上海证券交易所网站（www.sse.com.cn）上的《北 京凯因科技股份有限公司关于公司前期会计差错更正及财务报告、前期公告补充 披露的公告》（公告编号：2024-058）及《北京凯因科技股份有限公司2023年第 一季度 ...

证券代码：688687 证券简称：凯因科技 公告编号：2024-056 北京凯因科技股份有限公司 第六届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京凯因科技股份有限公司（以下简称"公司"）第六届董事会第五次会议 于2024年12月19日在公司会议室以现场结合通讯表决方式召开，根据《公司章程》 的相关规定，因本次会议为紧急会议，经全体董事一致同意豁免会议通知期限要 求，于2024年12月19日以口头方式通知全体董事、监事、高级管理人员召开本次 会议。会议应出席董事7名，实际出席董事7名。会议由董事长周德胜先生主持。 公司监事、高级管理人员列席了本次会议。会议的召集、召开程序符合《公司法》 和《公司章程》的相关规定。 二、董事会会议审议情况 会议以投票表决方式审议并通过了如下决议： （一）审议通过了《关于公司前期会计差错更正及财务报告、前期公告补充 披露的议案》 公司本次差错更正及追溯调整符合《企业会计准则第28号——会计政策、会 计估计变更和差错更正》《公开发行证券的 ...

证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 投资者关系活动记录表 （2024 年第三季度业绩说明会） - 1 - 北京凯因科技股份有限公司 关于 2024 年第三季度业绩说明会召开情况说明 2 / 5 | --- | --- | --- | |------------------|-------------------------|--------------------------------------------------------| | | □ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 业绩说明会 | | 投资者关系活动类 | □ | 新闻发布会 □路演活动 | | 别 | □ | 现场参观 □一对一沟通 | | | □ 其他（电话会议） | | | 时间 | 2024 年 12 月 | 06 日 15:00-16:00 | | 地点 | 公司会议室 | | | 会议召开方式 | 网络文字互动方式 | | | | 董事长兼总裁 周德胜先生 | | | 公司接待人员姓名 | | 副总裁、董事会秘书兼首席财务官 赫崇飞先生 | | | 独立董事 杜臣先生 ...